- Home
- VERV vs PEPG Comparison
VERV vs PEPG Comparison
Compare VERV & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERV
- PEPG
- Stock Information
- Founded
- VERV 2018
- PEPG 2018
- Country
- VERV United States
- PEPG United States
- Employees
- VERV N/A
- PEPG N/A
- Industry
- VERV Medicinal Chemicals and Botanical Products
- PEPG Biotechnology: Pharmaceutical Preparations
- Sector
- VERV Health Care
- PEPG Health Care
- Exchange
- VERV Nasdaq
- PEPG Nasdaq
- Market Cap
- VERV 382.5M
- PEPG 292.3M
- IPO Year
- VERV 2021
- PEPG 2022
- Fundamental
- Price
- VERV $5.46
- PEPG $8.87
- Analyst Decision
- VERV Strong Buy
- PEPG Strong Buy
- Analyst Count
- VERV 4
- PEPG 2
- Target Price
- VERV $26.00
- PEPG $23.00
- AVG Volume (30 Days)
- VERV 1.2M
- PEPG 92.9K
- Earning Date
- VERV 11-05-2024
- PEPG 11-06-2024
- Dividend Yield
- VERV N/A
- PEPG N/A
- EPS Growth
- VERV N/A
- PEPG N/A
- EPS
- VERV N/A
- PEPG N/A
- Revenue
- VERV $20,648,000.00
- PEPG N/A
- Revenue This Year
- VERV $57.08
- PEPG N/A
- Revenue Next Year
- VERV N/A
- PEPG N/A
- P/E Ratio
- VERV N/A
- PEPG N/A
- Revenue Growth
- VERV 279.70
- PEPG N/A
- 52 Week Low
- VERV $4.31
- PEPG $3.72
- 52 Week High
- VERV $20.12
- PEPG $19.30
- Technical
- Relative Strength Index (RSI)
- VERV 57.24
- PEPG 45.27
- Support Level
- VERV $4.37
- PEPG $8.54
- Resistance Level
- VERV $5.86
- PEPG $9.19
- Average True Range (ATR)
- VERV 0.32
- PEPG 0.51
- MACD
- VERV 0.12
- PEPG 0.03
- Stochastic Oscillator
- VERV 73.40
- PEPG 30.62
About VERV Verve Therapeutics Inc.
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.